{{Drugbox
| Verifiedfields = changed
| drug_name = 阿格列汀<br/>Alogliptin
| Watchedfields = changed
| verifiedrevid = 454952697
| IUPAC_name = 2-({6-[(3''R'')-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2''H'')-yl}methyl)benzonitrile
| image = Alogliptin Structural Formula V.1.svg

<!--Clinical data-->
| tradename = 尼欣那（Nesina，ネシーナ）
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = B
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| bioavailability = 100%
| protein_bound = 20%
| metabolism = 通过[[肝脏|肝脏]] ([[CYP2D6|CYP2D6]]和[[CYP3A4|CYP3A4]]）进行有限的代谢
| elimination_half-life = 12–21小时
| excretion = [[肾脏|肾脏]]（主要）和[[粪便|粪便]]（少量）

<!--Identifiers-->
| IUPHAR_ligand = 6319
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 850649-62-6
| ATC_prefix = A10
| ATC_suffix = BH04
| PubChem = 11450633
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 72323  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = JHC049LO86
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06553
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 376359
| synonyms = SYR-322

<!--Chemical data-->
| C=18 | H=21 | N=5 | O=2 
| molecular_weight = 339.39 g/mol
| smiles = N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC[C@@H](N)C2
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9625485
| InChI = 1/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
| InChIKey = ZSBOMTDTBDDKMP-OAHLLOKOBG
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZSBOMTDTBDDKMP-OAHLLOKOSA-N
}}

'''阿格列汀'''（{{lang-en|Alogliptin}}）， 商品名为'''尼欣那'''，是一种[[二肽基肽酶-4抑制剂|二肽基肽酶-4（DPP-4）抑制剂]]类口服[[抗糖尿病药|抗糖尿病药]]<ref name=pmid17441705/> ，由[[日本|日本]][[武田药品|武田药品]]研发于2005年。与其他治疗[[2型糖尿病|2型糖尿病]]的药物一样，阿格列汀不会增加[[心脏病|心脏病]]与[[中风|中风]]的风险。与其他[[列汀类药物|列汀类药物]]相似，阿格列汀几乎不会导致体重增加，并且导致低血糖的风险相对较低，有着适度的降糖活性。阿格列汀和其他列汀类药物一样常与[[二甲双胍|二甲双胍]]合用，用于无法单独用二甲双胍控制血糖的病人。<ref>{{cite web |url=https://www.aace.com/files/algorithm-07-11-2013.pdf |title=www.aace.com |format= |work= |accessdate= |archive-url=https://web.archive.org/web/20181101160532/https://www.aace.com/files/algorithm-07-11-2013.pdf |archive-date=2018-11-01 |dead-url=yes }}</ref>

==临床研究==
阿格列汀是一种[[二肽基肽酶-4抑制剂|二肽基肽酶-4（DPP-4）抑制剂]]，可以减缓肠促胰岛素激素[[GLP-1|GLP-1]]（胰高血糖素样多肽-1）和[[GIP|GIP]]（葡萄糖依赖性促胰岛素多肽）的失活速度。当血糖浓度正常或升高时，GLP-1和GIP 可通过涉及[[环磷腺苷|环磷腺苷]]的细胞内信号途径增加[[胰腺|胰腺β细胞]]合成并释放[[胰岛素|胰岛素]]。  <ref>http://www.takeda.com/news/2013/20130618_5841.html</ref>

===已报告的不良反应===
已报告的严重不良反应包括[[低血糖|低血糖]]、急性[[胰腺炎|胰腺炎]]、[[肝|肝]]功能异常、 [[黄疸|黄疸]]、[[Stevens-Johnson综合征|Stevens-Johnson综合征]]、[[多形性红斑|多形性红斑]]、[[横纹肌溶解症|横纹肌溶解症]]、[[肠梗阻|肠梗阻]]、[[间质性肺炎|间质性肺炎]]。<ref name=instruction>{{cite web |url=http://www.info.pmda.go.jp/go/pack/3969012F1025_1_14/ |title=ネシーナ錠25mg／ネシーナ錠12.5mg／ネシーナ錠6.25mg 添付文書 |date=2014-10 |accessdate=2015-03-26 }}{{dead link|date=2018年1月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>。临床试验仅发现了较低几率会导致轻度的低血糖。<ref name=seino2011/><ref name=kutoh2012/><ref name=bosi2011/>。

阿格列汀不会导致体重、[[心血管疾病|心血管疾病]]的风险和[[心脏病|心脏病]]风险的增加。<ref>{{cite journal |author=White WB, Cannon CP, Heller SR |title=Alogliptin after acute coronary syndrome in patients with type 2 diabetes |journal=N. Engl. J. Med. |volume=369 |issue=14 |pages=1327–35 |date=October 2013  |pmid=23992602 |doi=10.1056/NEJMoa1305889 |url=|display-authors=etal}}</ref><ref>{{cite journal |author=White WB, Zannad F |title=Saxagliptin, alogliptin, and cardiovascular outcomes |journal=N. Engl. J. Med. |volume=370 |issue=5 |pages=484 |date=January 2014  |pmid=24482824 |doi=10.1056/NEJMc1313880 |url=}}</ref>

==销售许可情况==
[[File:Nesina_Sales_In_China.jpg|thumb]]大陆销售的尼欣那®苯甲酸阿格列汀片，规格为25mg * 10片]]
在[[临床试验|III期临床试验]]取得了积极结果后，武田公司于2007年12月向[[FDA|FDA]]提交了新药申请。<ref name=grogan2012/><ref name=takedapr28864/> 2008年11月，武田公司也在日本申请了审批，并且在2010年4月通过了审批。<ref name=geneng2009/><ref name=grogan2012/>2012年，武田公司得到了FDA的负面回应，理由为需要更多的数据。阿格列汀最终于2013年通过了FDA的审批。

阿格列汀于2013年11月在中国上市，<ref>{{cite web |url=http://news.xinhuanet.com/health/2013-11/26/c_125762784.htm |title=新型Ⅱ型糖尿病治疗药物阿格列汀获准在中国上市 |format= |work= |accessdate=}}</ref>商品名为尼欣那（Nesina），是目前（2015年）国内最晚上市的列汀类药物。

==代谢==
阿格列汀不经过[[广泛代谢|广泛代谢]]，给药剂量的60-71%以原型通过尿液排泄。

在口服给予[<sup>14</sup>C]阿格列汀后，检测到2种次要[[代谢产物|代谢产物]]，N-去甲基化代谢物M-I（<1%母体化合物）和N-乙酰化代谢产物M-II（<6%，母体化合物）。M-I为活性代谢产物，对DPP-4的抑制活性与母体化合物相似；M-II对DPP-4或其他DPP相关酶均不具有抑制活性。体外数据显示，[[CYP2D6|CYP2D6]]和[[CYP3A4|CYP3A4]]参与阿格列汀有限的代谢作用。

阿格列汀主要以(R)-[[异构体|异构体]]（>99%）形式存在，在体内少量转化为(S)-异构体或不发生转化。在25mg剂量水平，未检测到(S)-异构体。<ref name=instruction/>

==引用==
{{reflist|3||refs=

<ref name=geneng2009>{{cite news
 |url=http://www.genengnews.com/news/bnitem.aspx?name=55661199&source=genwire
 |title=GEN News Highlights: Takeda Pulls MAA for Type 2 Diabetes Therapy |date=June 4, 2009
 |publisher=[[Genetic_Engineering_&_Biotechnology_News|Genetic Engineering & Biotechnology News]]
}}</ref>

<ref name=grogan2012>{{Citation
 |last=Grogan |first=Kevin |publication-date=April 26, 2012 |title=FDA wants yet more data on Takeda diabetes drug alogliptin
 |periodical=[[PharmaTimes|PharmaTimes]] |at=PharmaTimes online |publisher=PharmaTimes |accessdate=April 26, 2012
 |url=http://www.pharmatimes.com/Article/12-04-26/FDA_wants_yet_more_data_on_Takeda_diabetes_drug_alogliptin.aspx
}}</ref>

<ref name=pmid17441705>{{cite journal
 |last=Feng |first=Jun |last2=Zhang |first2=Zhiyuan |last3=Wallace |first3=Michael B. |last4=Stafford |first4=Jeffrey A.
 |last5=Kaldor |first5=Stephen W. |last6=Kassell |first6=Daniel B. |last7=Navre |first7=Marc |last8=Shi |first8=Lihong
 |last9=Skene |first9=Robert J. |last10=Asakawa |first10=Tomoko |last11=Takeuchi |first11=Koji |last12=Xu |first12=Rongda
 |last13=Webb |first13=David R. |last14=Gwaltney II |first14=Stephen L.
 |title=Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
 |journal=[[J._Med._Chem.|J. Med. Chem.]] |volume=50 |issue=10 |pages=2297–2300 |year=2007 |pmid=17441705 |doi=10.1021/jm070104l
}}</ref> 

<ref name=seino2011>{{Citation
 |last=Seino |first=Yutaka |last2=Fujita |first2=Tetsuya |last3=Hiroi |first3=Shinzo |last4=Hirayama |first4=Masashi
 |last5=Kaku |first5=Kohei |date=September 2011 |accessdate=April 26, 2012
 |title=Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study (abstract only)
 |journal=[[Current_Medical_Research_and_Opinion|Current Medical Research and Opinion]] |volume=27 |issue=9 |pages=1781–1792 |pmid=21806314
 |doi=10.1185/03007995.2011.599371 |url=http://informahealthcare.com/doi/abs/10.1185/03007995.2011.599371
}}</ref>

<ref name=kutoh2012>{{Citation |last=Kutoh |first=Eiji |last2=Ukai |first2=Yasuhiro |publication-date=January 17, 2012 |year=2012 |title=Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial (abstract only) |journal=[[Endocrine_(journal)|Endocrine]] |page= |pages= |pmid=22249941 |doi=10.1007/s12020-012-9596-0 |url=http://www.springerlink.com/content/g615228rv8p58748/ |accessdate=April 26, 2012 |archive-url=https://web.archive.org/web/20190713132451/https://link.springer.com/article/10.1007/s12020-012-9596-0 |archive-date=2019-07-13 |dead-url=yes }}</ref>

<ref name=bosi2011>{{Citation
 |last=Bosi |first=Emanuele |last2=Ellis |first2=G.C. |last3=Wilson |first3=C.A. |last4=Fleck |first4=P.R. |publication-date=October 27, 2011 |date=October 2011
 |title=Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study
 |journal=[[Diabetes,_Obesity_and_Metabolism|Diabetes, Obesity and Metabolism]] |volume=13 |issue=12 |publisher= |publication-place= |pages=1088–1096 |isbn= |oclc= |pmid= |doi=10.1111/j.1463-1326.2011.01463.x |url=http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1326.2011.01463.x/abstract |accessdate=April 26, 2012
}}</ref>

<ref name=takedapr28864>{{cite press release
 |url=http://www.takeda.com/press/article_28864.html
 |title=Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. |date=January 4, 2008 |accessdate=January 9, 2008
 |publisher=[[Takeda_Pharmaceutical_Company|Takeda Pharmaceutical Company]]
}}</ref>

}}

{{-}}

{{口服降糖药和胰岛素类似物}}
{{Diabetes}}

[[Category:武田药品工业|Category:武田药品工业]]
[[Category:糖尿病药物|Category:糖尿病药物]]
[[Category:腈|Category:腈]]
[[Category:哌啶|Category:哌啶]]
[[Category:酰亚胺|Category:酰亚胺]]
[[Category:嘧啶二酮|Category:嘧啶二酮]]